May 23, 2007 |
Allergan Inc., a maker of eye and beauty products, accused Canadian generic drug maker Apotex Inc. of infringing five U.S. patents for preparations used in the treatment of glaucoma. Allergan said in a federal lawsuit filed Monday in Delaware that Apotex told the company in April that it was seeking U.S. Food and Drug Administration approval to market generic versions of Allergan's Alphagan ophthalmic solution.
January 4, 2006 |
Allergan Inc. said it won a ruling temporarily blocking Apotex Inc. from making or selling a generic version of a treatment for eye inflammation. The ruling, issued Dec. 29 by U.S. District Judge Martin Jenkins in San Francisco, temporarily prohibits Apotex from manufacturing or selling a generic version of Allergan's Acular in the U.S., Allergan spokeswoman Caroline Van Hove said. Irvine-based Allergan, which also makes the anti-wrinkle drug Botox, sued Apotex over patents for Acular in 2001.
January 1, 2004 |
A federal judge in San Francisco on Wednesday upheld Allergan Inc.'s patent for its top-selling eye drug Acular, blocking Apotex Inc. from selling a competing product. The ruling may help Allergan in a government antitrust investigation. U.S. District Judge Martin Jenkins said Apotex could not sell a generic version of Acular until Allergan's patent expired in 2009. Acular is used to treat allergy, photophobia, post-surgical pain and post-surgical inflammation.
June 20, 2007 |
A Canadian company's generic version of the blood thinner Plavix has been blocked from the U.S. market until at least 2011. U.S. District Judge Sidney H. Stein said Tuesday that Apotex Inc. had failed to prove during a three-week trial in New York this year that the patent protecting Plavix from competitors was invalid. Apotex said it would file an immediate appeal with the U.S. Court of Appeals for the Federal Circuit in Washington.
May 19, 2005 |
A U.S. appeals court Wednesday gave generic-drug maker Apotex Inc. a second chance to seek the invalidation of a patent for Acular, Allergan Inc.'s treatment for eye inflammations. The U.S. Court of Appeals for the Federal Circuit in Washington ruled that a San Francisco judge committed a "clear error" when he concluded that Allergan's patent was valid because it wasn't an obvious variation of earlier known compounds.
September 1, 2006 |
Bristol-Myers Squibb Co. and Sanofi-Aventis on Thursday won a bid to stop Apotex Inc. from selling its cheaper generic version of the Plavix heart pill, the world's second-biggest-selling medicine. Bristol-Myers shares surged. U.S. District Court Judge Sidney H. Stein in New York ruled that Bristol-Myers and Sanofi were likely to win their patent-infringement suit against Apotex and wouldn't be able to recoup losses if generic sales were allowed to continue.